Ketryx, the agentic continuous compliance platform for safety-critical product development, announced today that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors and participated in the company’s Series B financing. The move underscores Ketryx's mission to streamline compliance in life sciences by leveraging AI to automate documentation and traceability.
Hawkins brings decades of leadership experience from Medtronic, the world’s largest medical device company, where he served as CEO from 2007 to 2011 and as chairman until 2014. His expertise in navigating regulatory landscapes is expected to guide Ketryx as it scales its platform for medical device, pharmaceutical, and robotics companies. The platform addresses a critical bottleneck: the manual, time-consuming process of generating compliant documentation and maintaining traceability across product lifecycles.
Ketryx's platform integrates with existing tools to automate documentation, create continuous traceability, and enable safe AI deployment. According to the company, its AI agents reduce manual work by up to 90 percent, helping teams identify and close compliance gaps faster. This is particularly relevant as regulators increasingly scrutinize software in medical devices and AI-driven diagnostics.
The appointment comes amid a broader industry push to accelerate innovation without compromising safety. Hawkins' involvement signals confidence in Ketryx's approach to solving compliance challenges that slow down product releases. “Ketryx is tackling one of the most pressing issues in life sciences: how to bring safer products to market faster while meeting rigorous regulatory standards,” Hawkins said in the announcement.
Ketryx, trusted by four of the world’s top five medical device manufacturers, aims to expand its reach. The Series B financing, in which Hawkins participated, will support further development of its agentic compliance platform. For more information, visit www.ketryx.com.
The announcement highlights the growing importance of AI in regulatory compliance, a trend that could reshape how life sciences companies approach product development. By automating compliance, Ketryx not only speeds up time-to-market but also reduces the risk of costly errors.
